Intravenous moxifloxacin launched

Bayer Schering has launched an intravenous preparation of moxifloxacin, Avelox, for the treatment of community acquired pneumonia and complicated skin and skin structure infections.

Moxifloxacin should only be given when it is considered inappropriate to use antibacterial agents that are commonly recommended and it should be used in accordance with local antibiotic guidelines.

Initial intravenous treatment may be followed by oral therapy when considered clinically appropriate; the recommended total duration of treatment is 7–21 days depending on the infection.

View Avelox IV drug record

Further information: Bayer Schering

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases